Literature DB >> 28954816

Effective Attenuation of Adenosine A1R Signaling by Neurabin Requires Oligomerization of Neurabin.

Yunjia Chen1, Christopher Booth1, Hongxia Wang1, Raymond X Wang1, Dimitra Terzi1, Venetia Zachariou1, Kai Jiao1, Jin Zhang1, Qin Wang2.   

Abstract

The adenosine A1 receptor (A1R) is a key mediator of the neuroprotective effect by endogenous adenosine. Yet targeting this receptor for neuroprotection is challenging due to its broad expression throughout the body. A mechanistic understanding of the regulation of A1R signaling is necessary for the future design of therapeutic agents that can selectively enhance A1R-mediated responses in the nervous system. In this study, we demonstrate that A1R activation leads to a sustained localization of regulator of G protein signaling 4 (RGS4) at the plasma membrane, a process that requires neurabin (a neural tissue-specific protein). A1R and RGS4 interact with the overlapping regions of neurabin. In addition, neurabin domains required for oligomerization are essential for formation of the A1R/neurabin/RGS4 ternary complex, as well as for stable localization of RGS4 at the plasma membrane and attenuation of A1R signaling. Thus, A1R and RGS4 each likely interact with one neurabin molecule in a neurabin homo-oligomer to form a ternary complex, representing a novel mode of regulation of G protein-coupled receptor signaling by scaffolding proteins. Our mechanistic analysis of neurabin-mediated regulation of A1R signaling in this study will be valuable for the future design of therapeutic agents that can selectively enhance A1R-mediated responses in the nervous system.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28954816      PMCID: PMC5676298          DOI: 10.1124/mol.117.109462

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  34 in total

Review 1.  Regulators of G-protein signalling as new central nervous system drug targets.

Authors:  Richard R Neubig; David P Siderovski
Journal:  Nat Rev Drug Discov       Date:  2002-03       Impact factor: 84.694

Review 2.  A finer tuning of G-protein signaling through regulated control of RGS proteins.

Authors:  Jacob Kach; Nan Sethakorn; Nickolai O Dulin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-04-27       Impact factor: 4.733

3.  Endogenous RGS proteins and Galpha subtypes differentially control muscarinic and adenosine-mediated chronotropic effects.

Authors:  Ying Fu; Xinyan Huang; Huailing Zhong; Richard M Mortensen; Louis G D'Alecy; Richard R Neubig
Journal:  Circ Res       Date:  2006-02-02       Impact factor: 17.367

4.  Distinct pathways of desensitization of A1- and A2-adenosine receptors in DDT1 MF-2 cells.

Authors:  V Ramkumar; M E Olah; K A Jacobson; G L Stiles
Journal:  Mol Pharmacol       Date:  1991-11       Impact factor: 4.436

5.  Negative cross-talk between presynaptic adenosine and acetylcholine receptors.

Authors:  A V Shakirzyanova; E A Bukharaeva; E E Nikolsky; R A Giniatullin
Journal:  Eur J Neurosci       Date:  2006-06-26       Impact factor: 3.386

Review 6.  Functions of neuronal adenosine receptors.

Authors:  H L Haas; O Selbach
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-11       Impact factor: 3.000

Review 7.  GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins.

Authors:  E M Ross; T M Wilkie
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

Review 8.  The role and regulation of adenosine in the central nervous system.

Authors:  T V Dunwiddie; S A Masino
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

Review 9.  Cellular regulation of RGS proteins: modulators and integrators of G protein signaling.

Authors:  Susanne Hollinger; John R Hepler
Journal:  Pharmacol Rev       Date:  2002-09       Impact factor: 25.468

Review 10.  Adenosine as a neuromodulator in neurological diseases.

Authors:  Detlev Boison
Journal:  Curr Opin Pharmacol       Date:  2007-10-17       Impact factor: 5.547

View more
  2 in total

Review 1.  Research progress on adenosine in central nervous system diseases.

Authors:  Ying-Jiao Liu; Jiao Chen; Xun Li; Xin Zhou; Yao-Mei Hu; Shi-Feng Chu; Ye Peng; Nai-Hong Chen
Journal:  CNS Neurosci Ther       Date:  2019-07-23       Impact factor: 5.243

2.  A peptide blocking the ADORA1-neurabin interaction is anticonvulsant and inhibits epilepsy in an Alzheimer's model.

Authors:  Shalini Saggu; Yunjia Chen; Liping Chen; Diana Pizarro; Sandipan Pati; Wen Jing Law; Lori McMahon; Kai Jiao; Qin Wang
Journal:  JCI Insight       Date:  2022-06-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.